Condition
Cryptococcal Infections
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.9% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 3 (1)
Trial Status
Completed2
Terminated1
Withdrawn1
Trial Success Rate
66.7%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05510973Not ApplicableCompleted
Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi
NCT03641131Completed
Ampholipad Real-World Data in Taiwan
NCT03002012Phase 3Terminated
Cryptococcal Antigen Screening Plus Sertraline
NCT03196921Phase 1WithdrawnPrimary
Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
Showing all 4 trials